Vitrolife´s CEO Magnus Nilsson goes from group responsibility to the transplantation business. Magnus Nilsson will focus on leading Xvivo Perfusion AB, a more independent operating unit within the Vitrolife Group.

“The transplantation product area is now in an intensive and exciting development phase, with decisive clinical trials and market introductions", says Magnus Nilsson. " I see a large potential value in our transplantation business which we will work hard to realize".

"Magnus knowledge about the research and commercial experience within the field is extensive and he will, as soon as it is suitable, leave the Vitrolife Group responsibility to focus on developing the Transplantation product area to a therapeutically as well as a commercial success" says Vitrolife´s chairman Patrik Tigerschiöld.

The recruitment of a new head of the fertility product area, also Group CEO, will commence immediately.